31430-38-3

Basic information

• Product Name: 1-(5-Bromo-2-pyridyl)-2-thiourea
• Synonyms: 1-(5-Bromo-2-pyridyl)-2-thiourea;N-(5-BroMo-2-pyridyl)thiourea, 97%;1-(5-bromopyridin-2-yl)thiourea;(5-Bromopyridin-2-yl)thiourea
• CAS NO: 31430-38-3
• Molecular Formula: C6H6BrN3S
• Molecular Weight: 232.1
• Mol File: 31430-38-3.mol
• Article Data: 4

Chemical Properties

• Melting Point: 236-240℃
• Boiling Point: 331.651 °C at 760 mmHg
• Flash Point: 154.377 °C
• Appearance: /
• Density: 1.828
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.764
• Storage Temp.: 2-8°C
• PKA: 11.69±0.70(Predicted)
• CAS DataBase Reference: 1-(5-Bromo-2-pyridyl)-2-thiourea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-Bromo-2-pyridyl)-2-thiourea(31430-38-3)
• EPA Substance Registry System: 1-(5-Bromo-2-pyridyl)-2-thiourea(31430-38-3)

Safety Data

• Hazardous Substances Data: 31430-38-3(Hazardous Substances Data)

Usage

General Description

1-(5-Bromo-2-pyridyl)-2-thiourea is a chemical compound with the molecular formula C7H7BrN3S. It is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active compounds. 1-(5-Bromo-2-pyridyl)-2-thiourea is known for its ability to form hydrogen bonding interactions, making it useful in the design and development of drug molecules. Additionally, it has been studied for its potential anti-inflammatory and antioxidant properties. Overall, 1-(5-Bromo-2-pyridyl)-2-thiourea is a versatile and important chemical compound with potential applications in the fields of drug development and biomedical research.

InChI:InChI=1/C6H6BrN3S/c7-4-1-2-5(9-3-4)10-6(8)11/h1-3H,(H3,8,9,10,11)

Upstream product

• 31430-37-2 N-(5'-bromo-2'-pyridyl)-N'-benzoylthiourea 
• 1072-97-5 5-bromo-2-pyridylamine 
• 1147550-11-5 ammonium thiocyanate 

Downstream Products

• 350511-12-5 (5-bromo-pyridine-2-yl)-thiazole-2-yl-amine 

Relevant articles and documents

PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS

Novel heterocyclic compounds of the formula (I) in which R1, R2, R3, R4 and D have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/o treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.

SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON

The present invention relates to a compound represented by Formula [I]: wherein X is O, S, NH or CH 2 ; Y 1 , Y 2 , Y 3 , Y 4 and Y 5 , which may be identical or different, are each CH or N; however, at least one of Y 1 , Y 2 , Y 3 , Y 4 and Y 5 is N; Z 1 and Z 2 , which may be identical or different, are each CH or N; n is an integer from 1 to 3; R 1 is a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aliphatic heterocyclic ring or an aromatic heterocyclic ring, or a bicyclic aliphatic saturated hydrocarbon group; R 2 and R 3 , which may be identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkenyl group, a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aromatic heterocyclic ring, or the like; and R 4 is a hydrogen atom, a lower alkyl group, a C 3 -C 6 cycloalkyl group or the like, or a pharmaceutically acceptable salt or ester thereof, and a selective inhibitor against Cdk4 and/or Cdk6 or an anticancer agent containing the compound or a pharmaceutically acceptable salt or ester thereof.